Author | Hatim Husain, MD

Articles

Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer

April 15, 2018

ByAjaz Bulbul, MD

Parissa K. Ferguson, MS

Fernando Lopez-Diaz, PhD

David S. Ettinger, MD

Hatim Husain, MD

In this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.

ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time

June 15, 2011

ByHatim Husain, MD

Charles M. Rudin, MD, PhD

Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation.

Radiotherapy in Small-Cell Lung Cancer

October 15, 2010

ByHatim Husain, MD

Christine L. Hann, MD, PhD

Russell Hales, MD

Ganti and colleagues have provided a brief review on the diagnosis of small-cell lung cancer (SCLC) and the roles of chemotherapy and surgery in its management. Notably, in the past three decades, the most significant progress in the treatment of SCLC has mainly involved the use of radiotherapy. Thus, to complement their assessment, we will provide an overview of the role of radiation in the management of limited-stage and extensive-stage SCLC.